Eletriptan
| Clinical data | |
|---|---|
| Trade names | Relpax, others |
| Other names | UK-116044; UK116044 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a603029 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | Serotonin 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F receptor agonist; Triptan; Antimigraine agent |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 50% |
| Metabolism | Mainly CYP3A4 |
| Elimination half-life | 4 hours |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEBI |
|
| ChEMBL |
|
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.167.337 |
| Chemical and physical data | |
| Formula | C22H26N2O2S |
| Molar mass | 382.52 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Eletriptan, sold under the brand name Relpax and used in the form of eletriptan hydrobromide, is a second-generation triptan medication intended for treatment of migraine headaches. It is used as an abortive medication, blocking a migraine attack which is already in progress. Eletriptan is marketed and manufactured by Pfizer.
Eletriptan is a therapeutic alternative on the World Health Organization's List of Essential Medicines.